These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 8024266)

  • 1. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.
    Arnold DL; Riess GT; Matthews PM; Francis GS; Collins DL; Wolfson C; Antel JP
    Ann Neurol; 1994 Jul; 36(1):76-82. PubMed ID: 8024266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions.
    Narayanan S; Fu L; Pioro E; De Stefano N; Collins DL; Francis GS; Antel JP; Matthews PM; Arnold DL
    Ann Neurol; 1997 Mar; 41(3):385-91. PubMed ID: 9066360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis.
    Pascual AM; Martínez-Bisbal MC; Boscá I; Valero C; Coret F; Martínez-Granados B; Marti-Bonmati L; Mir A; Celda B; Casanova B
    Neurology; 2007 Jul; 69(1):63-7. PubMed ID: 17606882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
    Parry A; Corkill R; Blamire AM; Palace J; Narayanan S; Arnold D; Styles P; Matthews PM
    J Neurol; 2003 Feb; 250(2):171-8. PubMed ID: 12574947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis.
    De Stefano N; Bartolozzi ML; Guidi L; Stromillo ML; Federico A
    J Neurol Sci; 2005 Jun; 233(1-2):203-8. PubMed ID: 15949506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.
    De Stefano N; Matthews PM; Fu L; Narayanan S; Stanley J; Francis GS; Antel JP; Arnold DL
    Brain; 1998 Aug; 121 ( Pt 8)():1469-77. PubMed ID: 9712009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging.
    Oh J; Pelletier D; Nelson SJ
    Arch Neurol; 2004 Jul; 61(7):1081-6. PubMed ID: 15262739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistics for investigation of multimodal MR imaging data and an application to multiple sclerosis patients.
    Fu L; Wolfson C; Worsley KJ; De Stefano N; Collins DL; Narayanan S; Arnold DL
    NMR Biomed; 1996 Dec; 9(8):339-46. PubMed ID: 9176888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
    Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis.
    Benedetti B; Rovaris M; Rocca MA; Caputo D; Zaffaroni M; Capra R; Bertolotto A; Martinelli V; Comi G; Filippi M
    Mult Scler; 2009 Jul; 15(7):789-94. PubMed ID: 19465450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between diffuse axonal damage and fatigue in multiple sclerosis.
    Tartaglia MC; Narayanan S; Francis SJ; Santos AC; De Stefano N; Lapierre Y; Arnold DL
    Arch Neurol; 2004 Feb; 61(2):201-7. PubMed ID: 14967766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging.
    Meyerhoff DJ; MacKay S; Constans JM; Norman D; Van Dyke C; Fein G; Weiner MW
    Ann Neurol; 1994 Jul; 36(1):40-7. PubMed ID: 8024260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging.
    Husted CA; Goodin DS; Hugg JW; Maudsley AA; Tsuruda JS; de Bie SH; Fein G; Matson GB; Weiner MW
    Ann Neurol; 1994 Aug; 36(2):157-65. PubMed ID: 8053651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo.
    Bruhn H; Frahm J; Merboldt KD; Hänicke W; Hanefeld F; Christen HJ; Kruse B; Bauer HJ
    Ann Neurol; 1992 Aug; 32(2):140-50. PubMed ID: 1324631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
    Rovaris M; Agosta F; Sormani MP; Inglese M; Martinelli V; Comi G; Filippi M
    Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis.
    Sarchielli P; Presciutti O; Tarducci R; Gobbi G; Alberti A; Pelliccioli GP; Chiarini P; Gallai V
    J Neurol; 2002 Jul; 249(7):902-10. PubMed ID: 12140676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study.
    Appenzeller S; Li LM; Costallat LT; Cendes F
    Brain; 2005 Dec; 128(Pt 12):2933-40. PubMed ID: 16195241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis.
    Narayana PA; Doyle TJ; Lai D; Wolinsky JS
    Ann Neurol; 1998 Jan; 43(1):56-71. PubMed ID: 9450769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis.
    Khan O; Shen Y; Bao F; Caon C; Tselis A; Latif Z; Zak I
    J Neuroimaging; 2008 Jul; 18(3):314-9. PubMed ID: 18304034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques.
    Arnold DL; Matthews PM; Francis GS; O'Connor J; Antel JP
    Ann Neurol; 1992 Mar; 31(3):235-41. PubMed ID: 1637131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.